Sath Shukla is CEO & President at Spero Therapeutics, Inc. (SPRO). They have made 3 open-market trades across 1 company since 2022, most recently 2025-02-05.
CIK 0001782817
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SPRO | SELL | 2025-02-05 | 2025-02-05 | $0.78 | $204K | -8.2% | -12.9% | -34.0% |
| SPRO | SELL | 2024-08-27 | 2024-08-29 | $1.35 | $4K | -2.9% | -2.9% | -18.1% |
| SPRO | SELL | 2024-08-02 | 2024-08-06 | $1.31 | $43K | -6.3% | +4.7% | +1.6% |
| SPRO | SELL · 10b5-1 | 2024-02-02 | 2024-02-05 | $1.43 | $173K | +4.8% | +18.6% | +14.5% |
| SPRO | SELL · 10b5-1 | 2023-08-28 | 2023-08-30 | $1.29 | $8K | -10.3% | -16.6% | -20.0% |
| SPRO | SELL · 10b5-1 | 2023-02-02 | 2023-02-03 | $1.83 | $17K | -4.3% | -18.7% | +0.5% |
| SPRO | SELL · 10b5-1 | 2022-08-29 | 2022-08-30 | $0.89 | $5K | +20.7% | +120.1% | +113.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.